Evaluation of the effect of apixaban on the primary intact intervertebral disc cell cultures (original) (raw)
Are the intervertebral disc tissue cells damaged when attempting to prevent thrombus formation with dabigatran which is amongst the new oral anticoagulants?
Necati Kaplan
Turkish Neurosurgery
View PDFchevron_right
Report of the Subcommittee on Control of Anticoagulation on the determination of the anticoagulant effects of apixaban: communication from the SSC of the ISTH
Christel Weiss
Journal of Thrombosis and Haemostasis
View PDFchevron_right
Effects of apixaban, rivaroxaban, dabigatran and enoxaparin on histopathology and laboratory parameters in Achilles tendon injury: An in vivo study
arzu gezer
Saudi Journal of Medicine and Medical Sciences, 2021
View PDFchevron_right
Tissue Distribution and Elimination of [14C]Apixaban in Rats
Larry Tremaine
Drug Metabolism and Disposition, 2011
View PDFchevron_right
In vitro effects of Apixaban on 5 different cancer cell lines
Alberto Giuseppe Passi
PloS one, 2017
View PDFchevron_right
Evaluation of the effect of apixaban using a viscoelastic coagulation assay with Russell’s viper venom reagent
Shoichi Uezono
2021
View PDFchevron_right
Comparative Metabolism of14C-Labeled Apixaban in Mice, Rats, Rabbits, Dogs, and Humans
Donglu Zhang
Drug Metabolism and Disposition, 2009
View PDFchevron_right
The safety and efficacy of apixaban: Where do we stand in 2013?
Flavio De Souza Brito
Expert Opinion on Drug Safety, 2013
View PDFchevron_right
Effects of Apixaban, Rivaroxaban, Dabigatran and Enoxaparin on Histopathology and Laboratory Parameters in Achilles Tendon Injury: An in vivo Study
arzu gezer
2021
View PDFchevron_right
Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor
Ola Saad
European Journal of Drug Metabolism and Pharmacokinetics, 2011
View PDFchevron_right
Role of apixaban (eliquis) in the treatment and prevention of thromboembolic disease
Anna Nogid
P & T : a peer-reviewed journal for formulary management, 2013
View PDFchevron_right
Evaluation of the effect of naproxen on the pharmacokinetics and pharmacodynamics of apixaban
Donglu Zhang
British Journal of Clinical Pharmacology, 2014
View PDFchevron_right
Oxaprozin: a NSAID able to inhibit the matrix metallo-proteinase activity
nicola franceschini
Inflammopharmacology, 2001
View PDFchevron_right
Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor
Donglu Zhang
Journal of Thrombosis and Thrombolysis, 2011
View PDFchevron_right
Reversal of Apixaban Induced Alterations in Hemostasis by Different Coagulation Factor Concentrates: Significance of Studies In Vitro with Circulating Human Blood
Jaume Roquer
PLoS ONE, 2013
View PDFchevron_right
Apixaban Metabolism and Pharmacokinetics after Oral Administration to Humans
Donglu Zhang
Drug Metabolism and Disposition, 2008
View PDFchevron_right
Pregabalin treatment for neuropathic pain may damage intervertebral disc tissue
Necati Kaplan
Experimental and therapeutic medicine, 2018
View PDFchevron_right
Investigation of the effects of methylphenidate, an amphetamine derivative, on intervertebral disc tissue cell cultures and matrix structures
Necati Kaplan
Turkish Neurosurgery
View PDFchevron_right
Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects
Jessie Wang
British Journal of Clinical Pharmacology, 2013
View PDFchevron_right
Captopril inhibits the 72 kDa and 92 kDa matrix metalloproteinases
Darius Sorbi
Kidney International, 1993
View PDFchevron_right
Matrix synthesis and degradation in human intervertebral disc degeneration
David Buttle
Biochemical Society Transactions, 2007
View PDFchevron_right
Extracellular Matrix Molecules: Potential Targets in Pharmacotherapy
Annele Sainio
Pharmacological Reviews, 2009
View PDFchevron_right
Differential inhibitory action of apixaban on platelet and fibrin components of forming thrombi: Studies with circulating blood and in a platelet-based model of thrombin generation
Juan Badimon
PloS one, 2017
View PDFchevron_right
Development and validation of LC-MS/MS method for determination of plasma apixaban
Marko Antunovic
2021
View PDFchevron_right
Multimodal assessment of non‐specific hemostatic agents for apixaban reversal
Pascale GAUSSEM
Journal of Thrombosis and Haemostasis, 2015
View PDFchevron_right
Assessment of low plasma concentrations of apixaban in the periprocedural setting
Ovidiu Vornicu
International Journal of Laboratory Hematology, 2020
View PDFchevron_right
Myocardial interaction of apixaban after experimental acute volume overload
Ari Mennander
Journal of International Medical Research, 2022
View PDFchevron_right
The new factor Xa inhibitor: Apixaban
Sangeeta Bhanwra
Journal of Pharmacology and Pharmacotherapeutics, 2014
View PDFchevron_right
Intradiscal injection of simvastatin results in radiologic, histologic, and genetic evidence of disc regeneration in a rat model of degenerative disc disease
Shayan Rahman
The Spine Journal, 2014
View PDFchevron_right